Ergoloid mesylate is a nootropic with an unknown mechanism of action indicated in individuals over sixty who manifest signs and symptoms of an idiopathic decline in mental capacity. Ergoloid Mesylate is an equiproportional preparation of three different ergotamantriones: dihydroergocornine, dihydroergocristine, and dihydroergocryptine.
- Mechanism
- Curator reviewed · 1 reference
The general mechanism of action of ergoloid mesylate is the dual action of partial agonism/antagonism of adrenergic, dopaminergic and serotonergic receptors. The pharmacological activity is determined by the degree of activity of each component at the receptor site. To know more about the individual components of the ergoloid mixture, please visit DB11275, DB11274, DB11273 and DB13345.
- Primary indication
- It was labeled by the FDA for the treatment of symptoms of an idiopathic decline in the mental capacity not related to a potentially reversible condition as well as for age-related cognitive impairment.Curator reviewed · 1 structured indication
- First approval
- Canada, 2004 · United States, 1983
- Also known as
- co-dergocrine mesilate · co-dergocrine mesylate · co-dergocrine methanesulfonate · codergocrine mesilate · codergocrine mesylate
- Brand names
Resolves to
What you can answer from here — as of July 17, 2026
Which other approved drugs treat the same conditions as Ergoloid mesylate, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account